Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin.
about
Enhancing oral vaccine potency by targeting intestinal M cellsEvaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMPMucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routesApplication of "Systems Vaccinology" to Evaluate Inflammation and Reactogenicity of Adjuvanted Preventative VaccinesInduction of intestinal immunity by mucosal vaccines as a means of controlling HIV infectionAdvances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccinesMucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbitsUse of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoproteinIntranasal immunization with recombinant HA and mast cell activator C48/80 elicits protective immunity against 2009 pandemic H1N1 influenza in miceImmune Adjuvant Effect of Molecularly-defined Toll-Like Receptor LigandsInfluenza vaccines: a moving interdisciplinary field.Intranasal vaccination with a plant-derived H5 HA vaccine protects mice and ferrets against highly pathogenic avian influenza virus challenge.An adjuvant for the induction of potent, protective humoral responses to an H5N1 influenza virus vaccine with antigen-sparing effect in mice.New technologies for influenza vaccines.Toxicity and immunogenicity of Enterotoxigenic Escherichia coli heat-labile and heat-stable toxoid fusion 3xSTa(A14Q)-LT(S63K/R192G/L211A) in a murine model.Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140.Immunogenicity of a West Nile virus DIII-cholera toxin A2/B chimera after intranasal deliveryEffective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.Subcutaneous Immunization with Fusion Protein DnaJ-ΔA146Ply without Additional Adjuvants Induces both Humoral and Cellular Immunity against Pneumococcal Infection Partially Depending on TLR4.Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine.Systemic and mucosal immune responses to sublingual or intramuscular human papilloma virus antigens in healthy female volunteers.Development of a Bacillus subtilis-based rotavirus vaccineMotor palsies of cranial nerves (excluding VII) after vaccination: reports to the US Vaccine Adverse Event Reporting System.Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives.Functional diversity of heat-labile toxins (LT) produced by enterotoxigenic Escherichia coli: differential enzymatic and immunological activities of LT1 (hLT) AND LT4 (pLT)A novel retinoic acid, catechin hydrate and mustard oil-based emulsion for enhanced cytokine and antibody responses against multiple strains of HIV-1 following mucosal and systemic vaccinations.Mucosal and systemic immune responses to Mycobacterium tuberculosis antigen 85A following its co-delivery with CpG, MPLA or LTB to the lungs in miceActivation of B cells by a dendritic cell-targeted oral vaccine.Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen.Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant.AB toxins: a paradigm switch from deadly to desirableMucosal immunization with a Staphylococcus aureus IsdA-cholera toxin A2/B chimera induces antigen-specific Th2-type responses in mice.The nasal dendritic cell-targeting Flt3 ligand as a safe adjuvant elicits effective protection against fatal pneumococcal pneumonia.Sublingual immunization with adenovirus F protein-based vaccines stimulates protective immunity against botulinum neurotoxin A intoxication.Maximal adjuvant activity of nasally delivered IL-1α requires adjuvant-responsive CD11c(+) cells and does not correlate with adjuvant-induced in vivo cytokine productionRepeated Aerosolized-Boosting with Gamma-Irradiated Mycobacterium bovis BCG Confers Improved Pulmonary Protection against the Hypervirulent Mycobacterium tuberculosis Strain HN878 in Mice.A combined vaccine approach against Vibrio cholerae and ETEC based on outer membrane vesicles.Shigella IpaB and IpaD displayed on L. lactis bacterium-like particles induce protective immunity in adult and infant mice.Heat-Labile Enterotoxin IIa, a Platform To Deliver Heterologous Proteins into Neurons.A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs.
P2860
Q21089613-623AEF96-8744-4300-A288-3EDB0C080AE5Q21090975-91D52C60-C61E-4407-9079-9C79C6159D2DQ22241377-2BBA2CB6-B826-4AFB-B643-D584302CC8B4Q26783957-C039F71E-931D-48D8-A7D2-F9E759323DE3Q27001897-C369AF2E-564E-4CDF-8D08-972149380821Q27013568-0FE6C1E1-F1B0-492F-A6E2-6CDA5416A4A5Q28476839-14E8AACA-D40D-4A46-81EB-EC4EDA21FF3BQ28730561-8BB17F00-5DBB-418F-A9A2-1B7A40EE5039Q28744391-6FDB7847-C977-4419-8B10-3E6937B425B0Q28972540-981176C1-0874-4B16-8496-BF9D58AE89D6Q30367695-2FF1D82D-7A91-4D3C-AC61-050CB243A1F7Q30372105-9D65581C-CB50-4DAE-BB10-EE326CA62C3BQ30390234-D05DC23A-AFFF-4F88-A325-E4E712C8F114Q30411859-3E4B72A0-7EA9-44A7-A923-B6333A549B69Q30416787-8E3FFD5A-EF76-4CAB-A55A-A5DB5C611B91Q31076192-FCD440C3-6955-4DDA-BE0C-EDC8E73B6769Q33584872-FB867743-876E-4CC8-99E1-5612C2EF19A2Q33665793-819AB832-6D9C-45D2-84BA-1485906594FAQ33785689-8EBA649B-C878-44A6-8360-C11F95BAE41BQ33909187-ED8A193D-288F-419A-BEC2-B1C7A53E2C85Q34206463-EC0DA1BD-D52C-4C7F-9019-BB8D6B781464Q34289936-5C220D76-3816-4A52-BB70-ADA337E15D04Q34290826-52632330-3F88-4CB2-AECE-9FFA605B1386Q34309830-410055E7-0B68-4721-A918-10BEC0492192Q34568384-371D88F5-8739-4A54-8262-44681EF719CDQ34663480-3F335023-98AD-4F08-9366-546F81161A97Q34722855-BAB39ADA-965A-4784-BC3D-10720C017DD1Q34979404-D0686C43-C020-4116-939A-48B02BD32C49Q34993838-EC676B66-04C9-4097-8138-2B9A0D4C6685Q35066293-A9C5C167-5823-4FBB-993B-0EC36D88D92FQ35155875-1A9F336D-EAF8-4626-9C9C-C49FB2E0C24EQ35191220-9AE9F9EB-21C8-4F98-95B0-EF85F2AFA2A2Q35328544-F12F37A1-807A-43FF-BBC6-962E893A3D3CQ35722157-25291060-65E5-424B-AE21-EF2E2B495E45Q35802766-320D8294-FDFF-4844-B03A-F672DC6AD71BQ35824421-6663567C-B426-45D1-BCEB-8697ED05F9F6Q35935738-62BA0914-73F1-4FFF-9DFE-90C3BABBDB92Q35946462-8D617E47-5333-40A6-B510-543013C46FC7Q35973003-E8D06805-DBB3-402A-97EF-C587BED99374Q35980530-38762957-063E-487A-A290-64ACC46F7ADE
P2860
Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin.
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Transient facial nerve paralys ...... richia coli heat labile toxin.
@ast
Transient facial nerve paralys ...... richia coli heat labile toxin.
@en
type
label
Transient facial nerve paralys ...... richia coli heat labile toxin.
@ast
Transient facial nerve paralys ...... richia coli heat labile toxin.
@en
prefLabel
Transient facial nerve paralys ...... richia coli heat labile toxin.
@ast
Transient facial nerve paralys ...... richia coli heat labile toxin.
@en
P2093
P2860
P1433
P1476
Transient facial nerve paralys ...... richia coli heat labile toxin.
@en
P2093
Birgit Thierry-Carstensen
David J M Lewis
Deborah Novicki
Eva Galiza
Giuseppe Del Giudice
Ingrid Kromann
Maria Woodrow
Rafaela Giemza
Susan Barnett
Zhiming Huo
P2860
P356
10.1371/JOURNAL.PONE.0006999
P407
P577
2009-09-16T00:00:00Z